These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 31924461)

  • 1. Impact of hepatic and renal impairment on the pharmacokinetics and tolerability of eliglustat therapy for Gaucher disease type 1.
    Li J; Chen J; Kanamaluru V; Gaemers SJM; Peterschmitt MJ; Hou AW; Xue Y; Turpault S; Rudin D
    Mol Genet Metab; 2020 Feb; 129(2):117-124. PubMed ID: 31924461
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Once- versus twice-daily dosing of eliglustat in adults with Gaucher disease type 1: The Phase 3, randomized, double-blind EDGE trial.
    Charrow J; Fraga C; Gu X; Ida H; Longo N; Lukina E; Nonino A; Gaemers SJM; Jouvin MH; Li J; Wu Y; Xue Y; Peterschmitt MJ
    Mol Genet Metab; 2018 Mar; 123(3):347-356. PubMed ID: 29358012
    [TBL] [Abstract][Full Text] [Related]  

  • 3. How a concentration-effect analysis of data from the eliglustat thorough electrocardiographic study was used to support dosing recommendations.
    Ruskin JN; Ortemann-Renon C; Msihid J; Ross L; Puga AC; Peterschmitt MJ; Cox GF; Maison-Blanche P
    Mol Genet Metab; 2020; 131(1-2):211-218. PubMed ID: 33012655
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Eliglustat: A Review in Gaucher Disease Type 1.
    Scott LJ
    Drugs; 2015 Sep; 75(14):1669-78. PubMed ID: 26384672
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-world effectiveness of eliglustat in treatment-naïve and switch patients enrolled in the International Collaborative Gaucher Group Gaucher Registry.
    Mistry PK; Balwani M; Charrow J; Kishnani P; Niederau C; Underhill LH; McClain MR
    Am J Hematol; 2020 Sep; 95(9):1038-1046. PubMed ID: 32438452
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcomes after 8 years of eliglustat therapy for Gaucher disease type 1: Final results from the Phase 2 trial.
    Lukina E; Watman N; Dragosky M; Lau H; Avila Arreguin E; Rosenbaum H; Zimran A; Foster MC; Gaemers SJM; Peterschmitt MJ
    Am J Hematol; 2019 Jan; 94(1):29-38. PubMed ID: 30264864
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety, tolerability, and pharmacokinetics of eliglustat tartrate (Genz-112638) after single doses, multiple doses, and food in healthy volunteers.
    Peterschmitt MJ; Burke A; Blankstein L; Smith SE; Puga AC; Kramer WG; Harris JA; Mathews D; Bonate PL
    J Clin Pharmacol; 2011 May; 51(5):695-705. PubMed ID: 20864621
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase 2 study of eliglustat tartrate (Genz-112638), an oral substrate reduction therapy for Gaucher disease type 1.
    Lukina E; Watman N; Arreguin EA; Banikazemi M; Dragosky M; Iastrebner M; Rosenbaum H; Phillips M; Pastores GM; Rosenthal DI; Kaper M; Singh T; Puga AC; Bonate PL; Peterschmitt MJ
    Blood; 2010 Aug; 116(6):893-9. PubMed ID: 20439622
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term adverse event profile from four completed trials of oral eliglustat in adults with Gaucher disease type 1.
    Peterschmitt MJ; Freisens S; Underhill LH; Foster MC; Lewis G; Gaemers SJM
    Orphanet J Rare Dis; 2019 Jun; 14(1):128. PubMed ID: 31174576
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcomes after 18 months of eliglustat therapy in treatment-naïve adults with Gaucher disease type 1: The phase 3 ENGAGE trial.
    Mistry PK; Lukina E; Ben Turkia H; Shankar SP; Baris H; Ghosn M; Mehta A; Packman S; Pastores G; Petakov M; Assouline S; Balwani M; Danda S; Hadjiev E; Ortega A; Gaemers SJM; Tayag R; Peterschmitt MJ
    Am J Hematol; 2017 Nov; 92(11):1170-1176. PubMed ID: 28762527
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and tolerability of zibotentan (ZD4054) in subjects with hepatic or renal impairment: two open-label comparative studies.
    Tomkinson H; Kemp J; Oliver S; Swaisland H; Taboada M; Morris T
    BMC Clin Pharmacol; 2011 Mar; 11():3. PubMed ID: 21414193
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Physiologically-Based Pharmacokinetic Model Development, Validation, and Application for Prediction of Eliglustat Drug-Drug Interactions.
    Sahasrabudhe SA; Cheng S; Al-Kofahi M; Jarnes JR; Weinreb NJ; Kartha RV
    Clin Pharmacol Ther; 2022 Dec; 112(6):1254-1263. PubMed ID: 36056771
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics and tolerability of fedratinib, an oral, selective Janus kinase 2 inhibitor, in subjects with renal or hepatic impairment.
    Ogasawara K; Smith WB; Xu C; Yin J; Palmisano M; Krishna G
    Cancer Chemother Pharmacol; 2020 Jun; 85(6):1109-1117. PubMed ID: 32449142
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A pooled analysis of adverse events in 393 adults with Gaucher disease type 1 from four clinical trials of oral eliglustat: Evaluation of frequency, timing, and duration.
    Peterschmitt MJ; Cox GF; Ibrahim J; MacDougall J; Underhill LH; Patel P; Gaemers SJM
    Blood Cells Mol Dis; 2018 Feb; 68():185-191. PubMed ID: 28126395
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management and monitoring recommendations for the use of eliglustat in adults with type 1 Gaucher disease in Europe.
    Belmatoug N; Di Rocco M; Fraga C; Giraldo P; Hughes D; Lukina E; Maison-Blanche P; Merkel M; Niederau C; Plӧckinger U; Richter J; Stulnig TM; Vom Dahl S; Cox TM
    Eur J Intern Med; 2017 Jan; 37():25-32. PubMed ID: 27522145
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of eliglustat on the pharmacokinetics of digoxin, metoprolol, and oral contraceptives and absorption of eliglustat when coadministered with acid-reducing agents.
    Thibault N; Ibrahim J; Peterschmitt MJ; Puga AC; Ross L; Vu L; Xue Y; Turpault S
    Mol Genet Metab; 2020 Apr; 129(4):278-285. PubMed ID: 32029355
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patient reported outcomes of patients with Gaucher disease type 1 treated with eliglustat in real-world settings: The ELIPRO study.
    Camou F; Lagadec A; Coutinho A; Berger MG; Cador-Rousseau B; Gaches F; Belmatoug N
    Mol Genet Metab; 2023 Nov; 140(3):107667. PubMed ID: 37597334
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Eliglustat tartrate for the treatment of adults with type 1 Gaucher disease.
    Bennett LL; Turcotte K
    Drug Des Devel Ther; 2015; 9():4639-47. PubMed ID: 26345314
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Type 1 Gaucher disease (CYP2D6-eliglustat).
    Becquemont L
    Therapie; 2017 Apr; 72(2):323-326. PubMed ID: 28242126
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.